Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early discontinuation of prednisone in FDG-PET/CT-negative idiopathic retroperitoneal fibrosis
2022-001692-13Phase 4Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of prednisone in Idiopathic retroperitoneal fibrosis (RPF), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Cumulative idiopathic retroperitoneal fibrosis relapse rate at month 21. Started Jun 2022; status: active.
02
Drugs
prednisone
03
Conditions
Idiopathic retroperitoneal fibrosis (RPF)
Beyond the preview
Go deeper on 2022-001692-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001692-13.